Open Nav

ViaCyte, Inc.

  • Paul Laikind, ViaCyte, Inc.

Connect with investors

  • Date:Wednesday, October 17
  • Time:2:00 PM - 2:15 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two product candidates in clinical-stage development: PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for high-risk type 1 diabetes patients. The PEC-Encap™ product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin.
  • Company
  • Company HQ City:San Diego
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Paul Laikind, Ph.D.
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :PEC-Encap
  • Development Phase of Primary Product:Phase II
  • Previous and Current Investors:JJDC, Sanderling, Asset Management
  • Total Amount Raised to Date, In All Rounds:$180M
Paul Laikind
ViaCyte, Inc.